sirp-alpha-fc fusion protein hcb101
sirp-alpha-fc fusion protein hcb101: 2 clinical trials tracked.
sirp-alpha-fc fusion protein hcb101 evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
What is verified about sirp-alpha-fc fusion protein hcb101, and what remains unknown?
Traceable citations · Unknowns marked
Clinical Trial Registry Records (2)
The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer
Primary endpoint: Number of subjects with MTD of HCB101 in combination with Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI
Phase Ib/IIa, Open-label, Multicenter, Dose Escalation, and Dose Expansion Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of HCB101 in Combination With Multiple Agents in Subjects With Advanced Solid Tumors
Primary endpoint: Number/incidence and percentage of subjects with adverse events.